BCL2 and acute myeloid leukemia: In November 2018, venetoclax (VEN), a small molecule Bcl2 inhibitor (i) in combination with hypomethylating agent (HMA: AZA or decitabine) was approved for the treatment of ND AML in patients aged ≥75 years and/or not eligible for intensive chemotherapy.